Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON47319
NL-OMON47319
Not yet recruiting
Not Applicable

ung cancer Early Molecular Assessment trial - Lung cancer Early Molecular Assessment trial:LEMA

Antoni van Leeuwenhoek Ziekenhuis0 sites1,297 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsnon-small cell lung cancer10038666

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
non-small cell lung cancer
Sponsor
Antoni van Leeuwenhoek Ziekenhuis
Enrollment
1297
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Antoni van Leeuwenhoek Ziekenhuis

Eligibility Criteria

Inclusion Criteria

  • •\- Suspicion of lung carcinoma or established NSCLC but awaiting start of definitive treatment
  • •\- Written informed consent to undergo diagnostic procedure and molecular analysis of the disease.

Exclusion Criteria

  • •\- Not motivated to receive any treatment at any point in time. Patients who consider undergoing treatment in the future are eligible.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
'A one-day diagnostic track for lung cancer suspects from chest X-ray using PET-CT and subsequent multiple endoscopic investigations. (including bronchoscopy, EUS-FNA and EBUS-TBNA)'.
NL-OMON29952Isala Klinieken100
Recruiting
Not Applicable
ung Cancer Genomic Screening Project for Neoadjuvant and Adjuvant setting Molecular Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer and the Assessment of monitoring Minimal Residual Diseaseung cancer
JPRN-UMIN000048977ational Cancer Center10,680
Active, not recruiting
Phase 1
A Phase I/II trial of UCB4594 in participants with advanced cancerAdvanced solid tumoursCancer
ISRCTN26628699Cancer Research UK167
Active, not recruiting
Phase 1
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Small Cell Lung Carcinoma (SCLC)Neuroendocrine Neoplasms
NCT05879978Boehringer Ingelheim45
Completed
Phase 1
A Phase I/IIa trial of BT1718 in patients with advanced solid tumours.
ISRCTN11160449Cancer Research UK66